Goserelin implant dosing regimens for improved patient compliance

A method of treating hormone receptor positive breast cancer in a patient, comprising

• administering a plurality of long-term IV chemotherapy cycles to the patient to provide a long-term course of chemotherapy,
• concomitantly administering an initial dose of a 3.6 mg goserelin acetate implant to the patient when a first of the plurality of long-term IV chemotherapy cycles is administered, and either
• i) 28-36 days after the initial dose of the 3.6 mg goserelin acetate implant, administering a second dose of the 3.6 mg goserelin acetate implant to the patient,
• optionally administering subsequent doses of the 3.6 mg goserelin acetate implant to the patient every 28-36 days, and
• after the second dose of the 3.6 mg goserelin acetate implant or the optional subsequent doses of the 3.6 mg goserelin acetate implant, discontinuing the 3.6 mg goserelin acetate implant, and administering a 10.8 mg goserelin implant to the patient once every 84 to 108 days,
• or
• ii) after the initial dose of the 3.6 mg goserelin acetate implant, discontinuing the 3.6 mg goserelin acetate implant, and administering a 10.8 mg goserelin implant to the patient once every 84 to 108 days,
• wherein in i) or ii) administering the 10.8 mg goserelin implant to the patient once every 84 to 108 days is continued for the lifetime of the patient.

A method of improving patient compliance, increasing duration of treatment, and/or reducing the need for oophorectomy in a patient with hormone receptor positive breast cancer comprises

• i) administering an initial dose of a 3.6 mg goserelin acetate implant to the patient,
• administering one or more subsequent doses of the 3.6 mg goserelin acetate implant to the patient, wherein each subsequent dose is prescribed to be administered 4 weeks after a preceding dose,
• identifying the patient as nonadherent if the patient does not receive the subsequent dose of 3.6 mg goserelin acetate implant at less than or equal to 36 days after the preceding dose,
• discontinuing the 3.6 mg goserelin acetate implant in the nonadherent patient,
• administering a 10.8 mg goserelin implant to the nonadherent patient, wherein the 10.8 mg goserelin implant is prescribed to be administered once every 12 weeks, and
• continuing to administer the 10.8 mg goserelin implant is administered once every 84 to 108 days to improve patient compliance, increase duration of treatment, and/or reduce the need for oophorectomy,
• wherein a course of treatment with a combination of 3.6 mg goserelin acetate implant and 10.8 mg goserelin implant is two years or the lifetime of the patient;
• or
• ii) administering an initial dose of a 3.6 mg goserelin acetate implant to the patient, wherein a subsequent dose is prescribed to be administered 4 weeks after the first dose,
• identifying the patient as nonadherent when the patient does not receive the subsequent dose of 3.6 mg goserelin acetate implant at less than or equal to 36 days after the first dose,
• discontinuing the 3.6 mg goserelin acetate implant in the nonadherent patient, and
• administering a 10.8 mg goserelin implant to the nonadherent patient, wherein the 10.8 mg goserelin implant is prescribed to be administered once every 12 weeks,
• wherein the 10.8 mg goserelin implant is administered once every 84 to 108 days for a minimum of eight doses to improve patient compliance, increase duration of treatment and/or reduce the need for oophorectomy.